Question explored with the scientific record
latest prostate cancer treatments
The evidence here is about late-stage, metastatic castration-resistant prostate cancer (mCRPC) treatments, not about early detection or prevention. The question asks about "latest" treatments, and the most recent trial here is from 2025, but it is a narrative review, not a new trial.
The evidence is dominated by studies funded by or closely tied to the manufacturers of the drugs they test. The COU-AA-301 and COU-AA-302 trials for abiraterone [2, 4] and the sipuleucel-T reanalysis [6] are the core of the evidence base. They show a survival benefit measured in months for men who have already progressed on chemotherapy. Abiraterone plus prednisone gave a median 4.6-month survival advantage over placebo in the post-docetaxel setting [2], and a 4.4-month advantage in chemotherapy-naive men [4]. The sipuleucel-T data is weaker: the survival advantage shrinks and loses statistical significance when adjusted for the fact that many control patients later received the same immunotherapy [6].
The newer approaches—Lu-177 PSMA radioligand therapy [8], neoadjuvant therapy before prostatectomy [13], and next-generation AR inhibitors like ODM-201 [14]—are supported by smaller, less mature, or purely preclinical evidence. The Lu-177 PSMA study [8] is a single-arm, retrospective analysis with a median follow-up of only 14.7 months and a 66.5% death rate, which tells you this is a very sick population, not a curative setting. The neoadjuvant review [13] explicitly states that no regimen has yet shown a clear survival benefit.
| Therapy | Setting | Median OS Benefit vs Control | Key Limitation |
|---|---|---|---|
| Abiraterone + prednisone | Post-docetaxel mCRPC | 4.6 months [2] | Manufacturer-funded; benefit in months, not years |
| Abiraterone + prednisone | Chemo-naive mCRPC | 4.4 months [4] | Manufacturer-funded; cardiac AEs doubled [4] |
| Sipuleucel-T | mCRPC | ~1.8 months (unadjusted) [6] | Benefit disappears with adjustment; manufacturer-funded |
| Lu-177 PSMA-617 | Heavily pre-treated mCRPC | Median OS 14.5 months [8] | Single-arm, no control group; 66.5% died during follow-up |
My call: for a man with mCRPC who has already failed chemotherapy, abiraterone offers a modest, statistically significant survival extension of a few months, but the evidence base is manufacturer-funded and the benefit is not large. The newer radioligand and targeted therapies lack the controlled trial data to justify a strong recommendation. Confidence: moderate for abiraterone in post-docetaxel mCRPC, low for all other agents and settings.
Sources examined 22
-
PD24-10 INTERIM ANALYSIS OF NCT02458716: FEASIBILITY OF CYTOREDUCTIVE PROSTATECTOMY IN MEN NEWLY DIAGNOSED WITH METASTATIC PROSTATE CANCER
This study investigates the predictors of visceral metastases (VM) in men with metastatic castration-resistant prostate cancer (mCRPC) and finds that VM is associated with shorter overall survival, while no demographic or tumor characteristics predict the presence of VM.
DOI: 10.1016/j.juro.2017.02.1087 -
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
The COU-AA-301 study demonstrates that abiraterone acetate significantly prolongs overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel treatment, with no new safety signals identified during extended follow-up.
DOI: 10.1016/s1470-2045(12)70379-0 -
Abiraterone prolongs survival in metastatic prostate cancer
The study highlights the effectiveness of abiraterone plus prednisone in prolonging overall survival in men with metastatic castration-resistant prostate cancer (CRPC) who have previously undergone docetaxel treatment.
DOI: 10.1038/nrclinonc.2011.111 -
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
This phase 3 study demonstrates that abiraterone acetate plus prednisone significantly improves overall survival compared to placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
DOI: 10.1016/s1470-2045(14)71205-7 -
Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results
The study evaluates radiographic progression-free survival (rPFS) as a response biomarker in metastatic castration-resistant prostate cancer (mCRPC) and demonstrates its strong association with overall survival (OS) in patients treated with abiraterone acetate plus prednisone co…
DOI: 10.1200/JCO.2014.55.3875 -
Survival Outcomes of Sipuleucel-T Phase III Studies: Impact of Control-Arm Cross-Over to Salvage Immunotherapy
A reanalysis of three phase III sipuleucel-T trials assessing whether control-arm cross-over to salvage APC8015F influenced overall survival, finding a possible salvage benefit that may have slightly inflated OS differences but suggesting the sipuleucel-T OS advantage could be m…
DOI: 10.1158/2326-6066.cir-15-0006 -
Clinical Impact of the Number of Treatment Cycles in First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer
This retrospective study investigates the survival outcomes of patients with metastatic castration-resistant prostate cancer treated with either 6 to 8 or 9 cycles of first-line docetaxel chemotherapy, finding that 9 cycles significantly improve overall survival.
DOI: 10.1016/j.clgc.2016.08.019 -
Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET
Post-therapy whole-body scintigraphy after two to three Lu-177 PSMA-617 cycles prognosticates overall survival in metastatic castration-resistant prostate cancer, correlating with interim PSMA-PET and offering a practical PET-sparing option during early treatment.
DOI: 10.1186/s40644-024-00773-w -
Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide
This study evaluates the clinical utility of the automated Bone Scan Index (BSI) as a quantitative imaging biomarker for predicting overall survival in metastatic castration-resistant prostate cancer patients treated with enzalutamide.
DOI: 10.1186/s13550-016-0173-z -
Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer
This study retrospectively reviews the oncologic outcomes of docetaxel-based chemotherapy in 257 Japanese men with metastatic castration-resistant prostate cancer, identifying significant predictors of overall survival.
DOI: 10.1016/j.urolonc.2011.06.006 -
Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate
This study evaluates the prostate-specific antigen (PSA) response and overall survival in 24 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide after progression on abiraterone following chemotherapy, finding a modest PSA response and…
DOI: 10.3109/21681805.2013.860189 -
Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data
This study developed a prognostic model for predicting overall survival in patients with metastatic castration-resistant prostate cancer through a crowdsourced challenge utilizing open clinical trial data, significantly outperforming previous models.
DOI: 10.1016/S1470-2045(16)30560-5 -
Treatment Intensification Prior to Radical Prostatectomy for Clinically Localized Prostate Cancer
A narrative review evaluating neoadjuvant therapy options (hormonal therapy, chemotherapy, immunotherapy, and radioligands) before radical prostatectomy in clinically localized high-risk prostate cancer, summarizing evidence, ongoing trials, and future directions while noting li…
DOI: 10.3390/cancers17132258 -
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
The study presents ODM-201, a novel androgen receptor inhibitor that effectively overcomes resistance mechanisms in castration-resistant prostate cancer, demonstrating significant antitumor activity and a favorable safety profile in preclinical models and early clinical trials.
DOI: 10.1038/srep12007 -
Role of Androgen Receptor in Melanoma: Mechanisms of Tumor Progression, Immune Evasion, and Therapeutic Implications
This review synthesizes current evidence on androgen receptor (AR) signaling in melanoma, detailing how AR promotes metastasis and immune evasion, contributes to therapy resistance, and how AR-targeted strategies (antagonists, degraders, PROTACs, RNAi, SARMs) could augment immun…
DOI: 10.3390/cancers17172828 -
Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
This is a comprehensive review of how androgen biosynthesis drives castration-resistant prostate cancer, evaluating CYP17A1 inhibition (notably abiraterone) and resistance mechanisms, and outlining future strategies—including combination therapies and development of more selecti…
DOI: 10.1158/1078-0432.ccr-12-0931 -
How splicing confers treatment resistance in prostate cancer
AR-V7, a truncated androgen receptor splice variant, enters the nucleus via a non-canonical import pathway that relies on its zinc finger D-box, moves continually within the nucleus, and supports a hit-and-run transcription model, revealing mechanistic differences from full-leng…
DOI: 10.7554/elife.82070 -
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer
This study investigates the synergistic effects of combining docetaxel with histone deacetylase inhibitors (HDACIs) on androgen receptor signaling in castration-resistant prostate cancer (CRPC) cells, demonstrating enhanced anti-proliferative effects and reduced levels of androg…
DOI: 10.1007/s10637-017-0529-x -
Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype
A comprehensive review synthesizing how prostate cancer evolves from genotype to phenotype, detailing canonical genomic alterations, signaling pathway crosstalk, and transitions from hormone-sensitive disease to castration-resistant and neuroendocrine states, with implications f…
DOI: 10.1016/j.critrevonc.2021.103370 -
Persistent androgen receptor addiction in castration-resistant prostate cancer
This review synthesizes how castration-resistant prostate cancer (CRPC) remains driven by persistent androgen receptor (AR) signaling—including canonical full-length AR, AR splice variants (notably AR-V7), intratumoral androgen synthesis, and cross-talk with other signaling path…
DOI: 10.1186/s13045-015-0225-2 -
Pharmacological Targeting of Constitutively Active Truncated Androgen Receptor by Nigericin and Suppression of Hormone-Refractory Prostate Cancer Cell Growth
This study identifies Nigericin as a novel inhibitor of androgen receptor signaling that reduces AR mRNA stability and protein levels (including constitutively active truncated AR), suppresses AR-driven PSA expression, and inhibits androgen-dependent and AR-variant–driven HRPC c…
DOI: 10.1124/mol.110.064790 -
Factors Implicated in Radiation Therapy Failure and Radiosensitization of Prostate Cancer
A comprehensive review identifying tissue biomarkers and signaling pathways that drive radiation therapy failure in prostate cancer and outlining potential radiosensitization strategies targeting AR signaling, outlaw/bypass/stem cell pathways, and inflammatory mediators to delay…
DOI: 10.1155/2012/593241